News

Sep 19, 2021 11:30 ET
Sep 19, 2021 11:30 ET
Sep 19, 2021 11:30 ET
Verastem Oncology Announces Updated Investigator-Sponsored Phase 1/2 FRAME Study Data of VS-6766 with Defactinib in Low-Grade Serous Ovarian Cancer Showing Encouraging Response Rates and Progression-F
Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced a mini oral presentation highlighting updated data from the ongoing investigator-sponsored Phase 1/2 FRAME study. The FRAME study, led by The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust, is investigating VS-6766, Verastem’s RAF/MEK inhibitor, in combination with defactinib, its FAK inhibitor, in patients with low grade serous ovarian cancer (LGSOC). The findings will be presented at the European Society of Medical Oncol
Sep 19, 2021 09:47 ET
Mirati Therapeutics Presents Positive Clinical Data with Investigational Adagrasib as Monotherapy and in Combination with Cetuximab in Patients with KRAS G12C-Mutated Colorectal Cancer
SAN DIEGO, Sept. 19, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced results from a cohort of the Phase 1/2 KRYSTAL–1 study evaluating adagrasib at the 600mg BID dose as both monotherapy and in combination with cetuximab in patients with heavily pretreated colorectal cancer harboring a KRASG12C mutation. Results showed that adagrasib alone and with cetuximab demonstrated significant clinical activity and broad disease control in these patients. The findings (Abstract # LBA6) will be presented today at 9:47 a.m. ET as
Sep 19, 2021 08:43 ET
PIEDMONT DEADLINE ALERT: Faruqi & Faruqi LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Piedmont To Contact Him Directly To Discuss
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Piedmont Lithium Inc. (“Piedmont” or the “Company”) (NASDAQ: PLL) and reminds investors of the September 21, 2021 deadline to seek the role of...
Sep 19, 2021 07:35 ET
Novartis presents new Kisqali® data showing longest median overall survival ever reported in HR+/HER2- advanced breast cancer
EAST HANOVER, N.J., Sept. 19, 2021 /PRNewswire/ -- Novartis today announced results of the final overall survival (OS) analysis of the Phase III MONALEESA-2 study, which evaluated Kisqali® (ribociclib) in combination with letrozole compared to placebo plus letrozole in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced or metastatic breast cancer with no prior systemic treatment for advanced disease. These data will be presented as a late-breaker oral presentation at the European Society for Medical Oncology (ESMO) Cong
Sep 19, 2021 07:30 ET
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Reduced Risk of Death by 27% Versus Chemotherapy as First-Line Treatment for Patients With Metastatic Triple-Negative Breast Cancer Whose Tumors Exp
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the final overall survival (OS) results from the pivotal Phase 3 KEYNOTE-355 trial investigating KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with chemotherapy (paclitaxel, nab-paclitaxel or gemcitabine/carboplatin) for the first-line treatment of patients with metastatic triple-negative breast cancer (mTNBC). KEYTRUDA is the first anti-PD-1 therapy in combination with chemotherapy to demonstrate a statistically significant and clinically meaningful improvement in OS for these patients.
Sep 19, 2021 03:00 ET
Toigo Foundation and B. Riley Financial Successful Conclusion of 2021 Summer MBA Investment Competition
OAKLAND. Calif., Sept. 19, 2021 /PRNewswire-PRWeb/ -- The Toigo Foundation and B. Riley Financial, Inc. (Nasdaq: RILY) are pleased to announce the successful culmination of the 2021 Summer MBA Investment Competition. Almost 50 MBAs participated in an immersive four-month summer program uniquely designed to facilitate industry education, mentorship, and the practical application of present-day business strategies led by experienced investment professionals from B. Riley.
Sep 18, 2021 23:00 ET
Johnson Controls Partners with Dubai Silicon Oasis Authority to Power Rochester Institute of Technology - Dubai
DUBAI, UAE, Sept. 18, 2021 /PRNewswire/ -- Johnson Controls (NYSE: JCI), the global leader for smart, healthy and sustainable buildings, today announced it is partnering with Dubai Silicon Oasis Authority (DSOA), the regulatory body of Dubai Silicon Oasis (DSO), the integrated free zone technology park, and the Rochester Institute of Technology Dubai (RIT Dubai) to deliver the region's first-of-its-kind smart, healthy, and sustainable new campus.
Sep 18, 2021 22:50 ET
Personalis Receives New VA MVP Task Order and Record Quarterly Orders From Oncology Customers; Reconfirms Total Revenue Outlook for 2021 with Further Accelerated Oncology Growth
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for population sequencing and cancer, today announced that the U.S. Department of Veterans Affairs Million Veteran Program (VA MVP) has issued a new task order under its current contract with the company, with a value of up to approximately $10 million. The company also announced that it has received, so far in Q3, more than $25M in orders from its oncology customers, a new record. Together these orders allow the company to reconfirm its total revenue outlook for 2021, with oncology revenue growth now projected to be at least 50% a
Sep 18, 2021 17:30 ET
SAM BREAKING NEWS: ROSEN, A LEADING AND LONGSTANDING LAW FIRM, Encourages The Boston Beer Company, Inc. Investors with Losses Exceeding $100K to Secure Counsel Before Important Deadline in Securities
WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of The Boston Beer Company, Inc. (NYSE: SAM) between April 22, 2021 and September 8, 2021, inclusive...
Sep 18, 2021 17:00 ET
ROSEN, NATIONAL TRIAL LAWYERS, Reminds Tyson Foods, Inc. Investors with Losses of the New September 30 Deadline in Securities Class Action – TSN
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Tyson Foods, Inc. (NYSE: TSN) between March 13, 2020 and December 15, 2020, both dates inclusive (the “Class Period”), of the September 30, 2021 lead...
Sep 18, 2021 16:45 ET
ROSEN, A LEADING LAW FIRM, Encourages Cassava Sciences, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – SAVA
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Cassava Sciences, Inc. (NASDAQ: SAVA) between September 14, 2020 and August 27, 2021, inclusive (the “Class Period”), of the important October 26, 2021...
Sep 18, 2021 16:30 ET
ROSEN, A TOP RANKED LAW FIRM, Encourages Sesen Bio, Inc. Investors with Losses to Secure Counsel Before Important October 18 Deadline in Securities Class Action – SESN
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Sesen Bio, Inc. (NASDAQ: SESN) between December 21, 2020 and August 17, 2021, inclusive (the “Class Period”), of the important October 18, 2021 lead...
Sep 18, 2021 16:12 ET
ROSEN, A TOP RANKED LAW FIRM, Encourages Katapult Holdings, Inc. f/k/a FinServ Acquisition Corp. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – KPLT, KP
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Katapult Holdings, Inc. f/k/a FinServ Acquisition Corp. (NASDAQ: KPLT, KPLTW, FSRV, FSRVU, FSRVW) between December 18, 2020 and August 10, 2021,...
Sep 18, 2021 16:12 ET
ROSEN, A TOP RANKED LAW FIRM, Encourages Katapult Holdings, Inc. f/k/a FinServ Acquisition Corp. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – KPLT, KP
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Katapult Holdings, Inc. f/k/a FinServ Acquisition Corp. (NASDAQ: KPLT, KPLTW, FSRV, FSRVU, FSRVW) between December 18, 2020 and August 10, 2021,...
Sep 18, 2021 11:30 ET
IMFINZI Plus Chemotherapy Tripled Patient Survival at Three Years in the CASPIAN Phase III Trial in Extensive-Stage Small Cell Lung Cancer
Updated results from the CASPIAN Phase III trial showed AstraZeneca’s IMFINZI® (durvalumab) in combination with a choice of chemotherapies, etoposide plus either carboplatin or cisplatin, demonstrated a sustained, clinically meaningful overall survival (OS) benefit at three years for adults with extensive-stage small cell lung cancer (ES-SCLC) treated in the 1st-line setting.
Sep 18, 2021 11:30 ET
IMFINZI plus chemotherapy tripled patient survival at three years in the CASPIAN Phase III trial in extensive-stage small cell lung cancer
Updated results from the CASPIAN Phase III trial showed AstraZeneca’s IMFINZI® (durvalumab) in combination with a choice of chemotherapies, etoposide plus either carboplatin or cisplatin, demonstrated a sustained, clinically meaningful overall survival (OS) benefit at three years for adults with extensive-stage small cell lung cancer (ES-SCLC) treated in the 1st-line setting.
Sep 18, 2021 11:24 ET
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts Sesen Bio (SESN) Investors to Lead Plaintiff Opportunity in Securities Class Action, Advises Investors with Significant Losses to Contact Firm’s Attorne
Hagens Berman urges Sesen Bio, Inc. (NASDAQ: SESN) investors with losses in excess of $250,000 to submit your losses now. Class Period: Dec. 21, 2020 – Aug. 17, 2021Lead Plaintiff Deadline: Oct. 18, 2021Visit:...
Sep 18, 2021 11:21 ET
OTLY 6-DAY DEADLINE ALERT: Hagens Berman Encourages Oatly Group (OTLY) Investors with Losses to Contact Firm’s Attorneys Now, Application Deadline Approaching in Securities Class Action
Hagens Berman urges Oatly Group AB (NASDAQ: OTLY) investors with significant losses to submit your losses now. A securities fraud class action has been filed and certain investors may have valuable claims. Class Period: May 20, 2021 – July 15,...
Sep 18, 2021 10:55 ET
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages ATI Physical Therapy (ATIP/FAII) Investors with Losses to Contact Firm’s Attorneys, Deadline Approaching in Securities Fraud Class Action
Hagens Berman urges ATI Physical Therapy, Inc. (NYSE: ATIP) investors and Fortress Value Acquisition Corp. II (NYSE: FAII) investors with losses in excess of $100,000 to submit your losses now. Class Period: Apr. 1, 2021 – July 23, 2021Lead...
Sep 18, 2021 10:55 ET
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages ATI Physical Therapy (ATIP/FAII) Investors with Losses to Contact Firm’s Attorneys, Deadline Approaching in Securities Fraud Class Action
Hagens Berman urges ATI Physical Therapy, Inc. (NYSE: ATIP) investors and Fortress Value Acquisition Corp. II (NYSE: FAII) investors with losses in excess of $100,000 to submit your losses now. Class Period: Apr. 1, 2021 – July 23, 2021Lead...
Sep 18, 2021 10:45 ET
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts Katapult Holdings (KPLT/FSRV) Investors to Securities Class Action, Encourages Investors with Losses to Contact Firm’s Attorneys Now
Hagens Berman urges Katapult Holdings, Inc. (NASDAQ: KPLT) investors and FinServe Acquisition Corp. (NASDAQ: FSRV) investors with significant losses to submit your losses now. Class Period: Dec. 18, 2020 – Aug. 10, 2021Lead Plaintiff Deadline:...
Sep 18, 2021 10:35 ET
HAGENS BERMAN Alerts View, Inc. (VIEW) Investors to Securities Class Action, Encourages Investors with Losses to Contact Firm’s Attorneys Now
Hagens Berman urges View, Inc. (NASDAQ: VIEW) investors with significant losses to submit your losses now. A securities fraud class action has been filed and certain investors may have valuable claims.   Class Period: Nov. 30, 2020 – Aug. 16,...
Sep 18, 2021 10:30 ET
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Reminds Zymergen (ZY) Investors of Securities Class Action, Encourages Investors with Losses to Contact Firm’s Attorneys Now
Hagens Berman urges Zymergen Inc. (NASDAQ: ZY) investors with significant losses to submit your losses now.    Class Period: Apr. 20, 2021 – Aug. 4, 2021Lead Plaintiff Deadline: Oct. 4, 2021Visit: www.hbsslaw.com/investor-fraud/ZY Contact An...
Sep 18, 2021 10:29 ET
ZY INVESTOR REMINDER: Kessler Topaz Meltzer & Check, LLP Announces Deadline in Securities Fraud Class Action Lawsuit Filed Against Zymergen Inc.
The law firm of Kessler Topaz Meltzer & Check, LLP announces that a securities fraud class action lawsuit has been filed in the United States District Court for the Northern District of California against Zymergen Inc. (NASDAQ: ZY) (“Zymergen”) on...
Sep 18, 2021 10:27 ET
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Live Ventures (LIVE) Investors with Losses to Contact Firm’s Attorneys Now, Deadline Approaching in Securities Class Action
Hagens Berman urges Live Ventures Incorporated (NASDAQ: LIVE) investors with significant losses to submit your losses now. Class Period: Dec. 28, 2016 – Aug. 3, 2021Lead Plaintiff Deadline: Oct. 12, 2021Visit: www.hbsslaw.com/investor-fraud/LIVE...
Sep 18, 2021 10:05 ET
ALERT: The Honest Company, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - HNST
SAN DIEGO, Sept. 18, 2021 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of The Honest Company, Inc. (NASDAQ: HNST) common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the "Registration Statement") issued in connection with Honest Company's May 2021 initial public offering ("IPO") have until November 15, 2021 to seek appointment as lead plaintiff.  The Honest Company class action lawsuit charges Honest Company, certain of its officers and directors, and the underwriters of the IPO with violations of t
Sep 18, 2021 10:02 ET
ARDX INVESTOR REMINDER: Kessler Topaz Meltzer & Check, LLP Announces Deadline in Securities Fraud Class Action Lawsuit Filed Against Ardelyx Inc.
The law firm of Kessler Topaz Meltzer & Check, LLP reminds Ardelyx Inc. (NASDAQ: ARDX) (“Ardelyx”) investors that a securities fraud class action lawsuit has been filed in the United States District Court for the Northern District of California...
Sep 18, 2021 09:33 ET
DEADLINE ALERT: Kessler Topaz Meltzer & Check, LLP Announces Deadline in Cassava Sciences, Inc. Securities Fraud Class Action Lawsuit
The law firm of Kessler Topaz Meltzer & Check, LLP announces that a securities fraud class action lawsuit has been filed in the United States District Court for the Western District of Texas against Cassava Sciences, Inc. (NASDAQ: SAVA) (“Cassava”)...
Sep 18, 2021 09:05 ET
ENHERTU® (fam-trastuzumab deruxtecan-nxki) reduced the risk of disease progression or death by 72% vs. trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer
Detailed positive results from the head-to-head DESTINY-Breast03 Phase III trial showed that ENHERTU® (fam-trastuzumab deruxtecan-nxki), the AstraZeneca and Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) HER2-directed antibody drug conjugate (ADC), demonstrated superior progression-free survival (PFS) versus trastuzumab emtansine (T-DM1), a HER2-directed ADC currently approved to treat patients with HER2-positive unresectable and/or metastatic breast cancer previously treated with trastuzumab and a taxane. Results were presented today in a Presidential Symposium at the
Sep 18, 2021 09:05 ET
Merck’s KEYTRUDA® (pembrolizumab) Demonstrated Superior Recurrence-Free Survival (RFS) in Patients With Resected High-Risk Stage II Melanoma Compared to Placebo in the Adjuvant Setting
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the first results from the Phase 3 KEYNOTE-716 trial, in which adjuvant treatment with KEYTRUDA, Merck’s anti-PD-1 therapy, showed a statistically significant and clinically meaningful improvement in recurrence-free survival (RFS), the trial’s primary endpoint, compared to placebo in patients with resected high-risk stage II melanoma; KEYTRUDA is the first anti-PD-1 therapy to demonstrate this.
Sep 18, 2021 09:05 ET
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy With or Without Bevacizumab Reduced Risk of Death by One-Third Versus Chemotherapy With or Without Bevacizumab as First-Line Treatment for Persisten
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the presentation of the full results from the pivotal Phase 3 KEYNOTE-826 trial investigating KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with chemotherapy with or without bevacizumab for the first-line treatment of persistent, recurrent or metastatic cervical cancer at the European Society for Medical Oncology (ESMO) Congress 2021 (Abstract #LBA2). These data were also simultaneously published in the New England Journal of Medicine. This is the first combination regimen with an anti-PD-1/PD-L1
Sep 18, 2021 09:05 ET
WDH DEADLINE: Investors with Substantial Losses Have Opportunity to Lead the Waterdrop Inc. Class Action Lawsuit
SAN DIEGO, Sept. 18, 2021 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Waterdrop Inc. (NYSE: WDH) American Depositary Shares ("ADSs") pursuant and/or traceable to Waterdrop's May 2021 initial public offering ("IPO") have until November 15, 2021 to seek appointment as lead plaintiff in the Waterdrop class action lawsuit.  Filed by Robbins Geller, the Waterdrop class action lawsuit charges Waterdrop, certain of its top executives and directors, as well as the underwriters of Waterdrop's IPO with violations of the Securities Act of 1933.  The Wa
Sep 18, 2021 08:45 ET
Spectrum Pharmaceuticals Presents Late Breaker Oral Presentation of Poziotinib Data in First-Line NSCLC Patients with HER2 Exon 20 Insertion Mutations at ESMO Congress 2021
Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced the presentation of safety and efficacy results from Cohort 4 of the ZENITH20 clinical trial. This data is from 48 first-line patients with non-small cell lung cancer (NSCLC) with HER2 exon 20 insertion mutations who received 16mg of oral poziotinib once daily. These results showed a confirmed objective response rate (ORR) of 44%, as evaluated centrally by an independent image review committee using RECIST 1.1 criteria. The data was presented as a late
Sep 18, 2021 08:18 ET
COINBASE DEADLINE ALERT: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Coinbase To Contact Him Directly To Discuss The
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Coinbase Global, Inc (“Coinbase” or the “Company”) (NASDAQ: COIN) and reminds investors of the September 20, 2021 deadline to seek the role of...
Sep 18, 2021 08:00 ET
Portnoy Law: Lawsuit Filed On Behalf of Live Ventures Incorporated Investors
The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of Live Ventures Incorporated ("Live" or "the Company") (NASDAQ : LIVE) investors that acquired securities between December 28, 2016 and August 3, 2021....
Sep 18, 2021 07:30 ET
ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated robust and durable tumor response of 54.9% in patients with HER2-mutant metastatic non-small cell lung cancer
Detailed primary results from the positive Phase II DESTINY-Lung01 trial of ENHERTU® (fam-trastuzumab deruxtecan-nxki), the AstraZeneca and Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) HER2-directed antibody drug conjugate (ADC), showed a robust and durable tumor response in previously treated patients with HER2-mutant (HER2m) unresectable and/or metastatic non-squamous non-small cell lung cancer (NSCLC). Results presented during a late-breaking Proffered Paper session at the European Society for Medical Oncology (ESMO) Congress 2021 and simultaneously published in
Sep 18, 2021 07:30 ET
Exelixis Announces Detailed Phase 1b Results from Cohort 6 of COSMIC-021 Trial in Patients with Metastatic Castration-Resistant Prostate Cancer Presented at ESMO 2021
Exelixis, Inc. (Nasdaq: EXEL) today announced detailed results from the expanded cohort 6 of the phase 1b COSMIC-021 trial of cabozantinib (CABOMETYX®) in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer (CRPC). Cohort 6 included patients with metastatic CRPC who had been previously treated wit
Sep 18, 2021 06:00 ET
World's First Hybrid NFT Company To Be Listed In The United States - Bonanza Goldfields Corp Enters Into A Memorandum of Understanding To Acquire Hybrid NFT Firm Marvion™ media Limited
SINGAPORE, Sept. 18, 2021 /PRNewswire/ -- Bonanza Goldfields Corp (OTC: BONZ) is pleased to announce that it has signed a MOU to acquire 100% of Marvion™ Media Limited.
Sep 18, 2021 03:40 ET
FDA Advisory Committee Votes Unanimously in Favor of COMIRNATY® Booster for Emergency Use in People 65 and Older and Certain High-Risk Populations
Committee reviewed clinical data showing a booster dose of COMIRNATY® elicits high neutralization titers against SARS-CoV-2 and all currently tested variants Reactogenicity profile within seven days of the booster dose was typically mild to...
Sep 17, 2021 23:31 ET
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Cornerstone OnDemand, Inc. - CSOD
NEW YORK, Sept. 17, 2021 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018-2020 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating Cornerstone OnDemand, Inc. ("CSOD" or the "Company") (CSOD) relating to its proposed acquisition by Clearlake Capital Group, LP. Under the terms of the agreement, CSOD shareholders will receive $57.50in cash per share they own.
Sep 17, 2021 22:50 ET
COINBASE GLOBAL 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuits Against Coi
Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until September 20, 2021 to file lead plaintiff applications in securities class action lawsuits against Coinbase Global Inc. (NasdaqGS: COIN), if they purchased the Company’s shares issued in connection with its April 2021 Direct Offering (the "Offering"). These actions are pending in the United States District Court for the Northern District of California.
Sep 17, 2021 22:50 ET
EHEALTH INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of eHealth, Inc. - EHTH
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into eHealth, Inc. (NasdaqGS: EHTH).
Sep 17, 2021 22:50 ET
FACEBOOK INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Facebook, Inc. - FB
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Facebook, Inc. (NasdaqGS: FB).

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please subscribe. Our packages start at $1.00 plus tax for the first month.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.